Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

Mr Mohammad Abul Qasem

22 Apr 2014 07:01

RNS Number : 1619F
Beximco Pharmaceuticals Ltd
22 April 2014
 



BEXIMCO PHARMACEUTICALS LTD.

 

 

22nd April, 2014

 

 

Mr Mohammad Abul Qasem

 

Beximco Pharmaceuticals Limited (or "the Company"; LSE-AIM: BXP) announces with sadness the death of Mohammad Abul Qasem, a Director of the Company, on 19 April 2014.

 

Ahmed Sohail Fasiur Rahman, Chairman of Beximco Pharmaceuticals, said: "The Board of Directors recall with appreciation and gratitude Mohammad Abul Qasem's contribution towards the establishment and growth of Beximco Pharmaceuticals Ltd. The Beximco Pharma Family extends their deepest sympathy and sincerest condolences to the bereaved members of his family at his sad demise."

 

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

 

Daniel Stewart & Company (NOMAD and Broker)

Emma Earl

James Thomas

Tel: +44 (0)20 7776 6550

 

FTI Consulting

Simon Conway/ Victoria Foster-Mitchell

Tel: +44 (0)20 3727 1000

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

 

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIBMRTMBMTBBI
Date   Source Headline
27th Dec 20177:00 amRNSAGM Statement
30th Nov 201710:30 amRNSBeximco Pharma wins at Scrip Awards 2017
23rd Nov 201711:53 amRNSNotice of AGM
14th Nov 20177:00 amRNSResults for First Quarter Ended 30 September 2017
7th Nov 20177:00 amRNSCommencement of Second Product Export to the US
6th Nov 201710:30 amRNSResults for the 12 month period ended 30 June 2017
26th Oct 20177:00 amRNSNotice of Preliminary Results and AGM
6th Oct 20177:00 amRNSSigns a Non-Binding MoU with Nuvista Pharma
2nd Oct 20177:00 amRNSChange of Broker
18th Sep 20177:00 amRNSCommences Export to Canada
25th Jul 20177:00 amRNSFDA approves Beximco Pharma Methocarbamol tablets
28th Apr 20177:00 amRNSFinancial Results for the Third Quarter of 2016-17
27th Jan 20177:00 amRNSHalf year results 2016-17
25th Jan 20177:00 amRNSBeximco Pharma forms JV with BioCare Manufacturing
19th Dec 20167:00 amRNSUS FDA approves Metformin for diabetes control
16th Dec 201610:12 amRNSPayment of Cash Dividend
12th Dec 20161:54 pmRNSStock Dividend Issued and Total Voting Rights
21st Nov 20167:00 amRNSAGM Statement
15th Nov 20167:00 amRNS1st Quarter Results
25th Oct 20167:00 amRNSReceives second product approval from the US FDA
20th Oct 20167:00 amRNSResults for the 18 month period ended 30 June 2016
19th Oct 20167:00 amRNSNotice of AGM
7th Oct 20167:00 amRNSNotification of Preliminary Results and AGM
5th Aug 20167:00 amRNSBeximco Pharma commences export to the US
17th Jun 20167:00 amRNSBeximco Pharma commences export to Kuwait
9th May 20167:00 amRNSFinal Results
6th May 20167:01 amRNSAGM Change and Dividend Update
6th May 20167:00 amRNSChange of Accounting Reference Date
4th May 20167:00 amRNSAmendment to Notification of Preliminary Results
21st Apr 20167:00 amRNSNotification of Preliminary Results and AGM
19th Nov 20157:00 amRNSUS FDA approval to manufacture blood pressure drug
27th Oct 20157:00 amRNS3rd Quarter Results
24th Jul 20157:00 amRNSHalf Yearly Report
13th Jul 201510:53 amRNSPayment of Cash Dividend
26th Jun 20157:00 amRNSStock Dividend Issued and Total Voting Rights
24th Jun 20157:00 amRNSBeximco Pharma receives US FDA approval
15th Jun 20157:00 amRNSAGM Statement
14th May 20157:00 amRNSFirst Quarter Results
12th May 20157:01 amRNSAGM Notification
11th May 20157:00 amRNSAnnual Financial Report
28th Apr 20157:00 amRNSNotification of Preliminary Results and AGM
2nd Feb 20157:00 amRNSBeximco Pharma completes US FDA Audit
28th Jan 20157:00 amRNSEnters into new Loan Agreement to fund expansion
19th Jan 201512:42 pmRNSBeximco Pharma commences export to Australia
12th Dec 20147:00 amRNSAppointment of Nominated Adviser
24th Nov 20147:00 amRNSReceives GMP Approval from Health Canada
3rd Nov 20147:00 amRNSBoard Appointment
30th Oct 20147:00 amRNSFinancial Results for the Third Quarter of 2014
24th Jul 20147:00 amRNSHalf Yearly Report
14th Jul 20143:44 pmRNSPayment of Cash Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.